Phospho-STK39 (S325) Antibody

What is STK39 and what cellular functions is it involved in?

STK39 (Serine/Threonine Kinase 39), also known as SPAK (STE20/SPS1-related Proline-Alanine-rich Kinase), functions as a key component in cellular stress response pathways. It is a serine/threonine kinase that is activated in response to hypotonic stress, leading to phosphorylation of several cation-chloride-coupled cotransporters. The protein specifically activates the p38 MAP kinase pathway, and its interaction with p38 decreases upon cellular stress, suggesting that STK39 serves as an intermediate in the cellular stress response mechanism . Additionally, research has shown that STK39 positively regulates the ERK signaling pathway and interacts with PLK1 (Polo-like kinase 1), indicating its involvement in multiple signaling networks within the cell . STK39 is predominantly expressed in brain and pancreas, with lower expression levels in heart, lung, kidney, skeletal muscle, liver, placenta, and testis .

What are the common phosphorylation sites on STK39 and their significance?

Several key phosphorylation sites have been identified on STK39 that regulate its activity and function:

These phosphorylation sites are essential for STK39's role in cellular signaling cascades. Phosphorylation at these sites is typically induced by upstream kinases in response to cellular stress or other stimuli. Monitoring these phosphorylation events is critical for understanding STK39 activation status in experimental contexts .

What applications is the Phospho-STK39 (S325) Antibody suitable for?

The Phospho-STK39 (S325) Antibody is validated for multiple experimental applications:

When designing experiments, it's important to note that optimal dilutions may vary depending on the specific antibody source and sample type. Preliminary titration experiments are recommended to determine ideal concentrations for your specific experimental conditions . The antibody specifically detects endogenous levels of STK39 only when phosphorylated at serine 325, making it valuable for studying activation status rather than total protein levels .

How can I validate the specificity of Phospho-STK39 (S325) Antibody in my experimental system?

Validating antibody specificity is critical for reliable research outcomes. For Phospho-STK39 (S325) Antibody, a comprehensive validation approach should include:

• Phosphatase treatment control: Split your sample into two portions and treat one with lambda phosphatase. The Phospho-STK39 (S325) signal should disappear in the treated sample while total STK39 remains detectable.

• CRISPR/Cas9 knockout verification: Generate STK39-knockout cell lines following protocols similar to those described in the literature, such as using the target sequence 5ʹ-CGGCGGCACAGGCTGTCGGC-3ʹ for CRISPR/Cas9-mediated knockout. This provides a negative control for antibody specificity testing .

• Phosphomimetic mutant analysis: Create S325A (non-phosphorylatable) and S325D/E (phosphomimetic) mutants of STK39. The antibody should not recognize the S325A mutant but may partially recognize the phosphomimetic variant.

• Induced phosphorylation: Stimulate cells with hypotonic stress or other known activators of STK39 and monitor increased phosphorylation signal as validation of responsiveness.

• Peptide competition assay: Pre-incubate the antibody with the phosphorylated peptide immunogen to block specific binding sites. This should eliminate specific staining in your application of choice.

The combination of these approaches provides robust validation of antibody specificity and ensures reliable experimental results .

What is the relationship between STK39 phosphorylation and disease states, particularly in hypertension and cancer?

STK39 phosphorylation status has been implicated in multiple disease states:

Hypertension and Renal Function:
SPAK-knockout mice (Stk39-null) manifest Gitelman syndrome, characterized by hypocalciuria, hypomagnesemia, and hypokalemic metabolic alkalosis. These mice show blunted response to hydrochlorothiazide (HCTZ) but normal response to furosemide, indicating altered renal ion transport regulation . This suggests that STK39 phosphorylation and subsequent activation regulate blood pressure through effects on renal salt handling, making STK39 a promising target for antihypertensive therapy development .

Cancer Progression:
RNA sequencing analysis has revealed that STK39 positively regulates the ERK signaling pathway, which is frequently dysregulated in cancer. Mass spectrometry studies have identified interactions between STK39 and PLK1, a key regulator of cell cycle progression . In hepatocellular carcinoma (HCC) research, STK39-knockdown models show altered gene expression profiles, suggesting a role in cancer progression through multiple signaling pathways .

Understanding phosphorylation-specific functions of STK39 in these contexts requires careful experimental design with phospho-specific antibodies like the Phospho-STK39 (S325) Antibody to monitor activation status in disease models and patient samples.

How do I design experiments to investigate the functional consequences of STK39 phosphorylation at Serine 325?

To investigate functional consequences of STK39 S325 phosphorylation, consider this comprehensive experimental approach:

• Site-directed mutagenesis studies:

  • Generate S325A (non-phosphorylatable) and S325D/E (phosphomimetic) mutants

  • Compare kinase activity using in vitro kinase assays with known substrates

  • Assess cellular localization changes using immunofluorescence microscopy

  • Evaluate protein-protein interactions through co-immunoprecipitation studies

• Phosphorylation-specific signaling analysis:

  • Monitor downstream pathway activation (p38 MAPK, ERK) using phospho-specific antibodies

  • Perform time-course experiments following cell stimulation (hypotonic stress, growth factors)

  • Compare wild-type vs. mutant reconstitution in STK39-knockout backgrounds

• Functional readouts:

  • Assess ion transporter activity for Na+-K+-2Cl− cotransporters and Na+-Cl− cotransporters

  • Measure cell migration, proliferation, and survival under various stress conditions

  • Evaluate in vivo phenotypes using animal models with S325A knock-in mutations

• Structural biology approach:

  • Use molecular dynamics simulations to predict structural changes upon S325 phosphorylation

  • Consider X-ray crystallography or cryo-EM studies comparing phosphorylated vs. non-phosphorylated forms

These multifaceted approaches would collectively provide insights into how S325 phosphorylation mechanistically regulates STK39 function in cellular contexts .

What are the best practices for using Phospho-STK39 (S325) Antibody in immunohistochemistry for tissue analysis?

Optimizing immunohistochemistry (IHC) protocols for Phospho-STK39 (S325) Antibody requires attention to several critical factors:

• Tissue fixation considerations:

  • For optimal phospho-epitope preservation, use freshly collected tissues and fix immediately

  • PFA fixation (4%) for 24 hours is recommended for phosphorylated protein detection

  • Avoid prolonged fixation which can mask epitopes and reduce signal intensity

  • Consider using phosphatase inhibitors in fixatives to preserve phosphorylation status

• Antigen retrieval optimization:

  • Test both heat-induced epitope retrieval (HIER) methods: citrate buffer (pH 6.0) and EDTA buffer (pH 9.0)

  • For Phospho-STK39 (S325), heated EDTA buffer often yields superior results

  • Optimize retrieval time (10-20 minutes) to maximize signal while minimizing background

• Antibody incubation parameters:

  • Initial dilution range: 1:50-1:100 as recommended

  • Incubation time: Overnight at 4°C typically yields best signal-to-noise ratio

  • Include phosphatase inhibitors in diluents to prevent epitope degradation

  • Use appropriate blocking reagents to minimize non-specific binding

• Detection system selection:

  • For low abundance phospho-proteins, amplification systems like tyramide signal amplification may improve detection

  • Use double staining with total STK39 antibody (on sequential sections) for validation

• Controls for phospho-specific staining:

  • Adjacent sections treated with lambda phosphatase as negative controls

  • Tissues with known STK39 activation (brain, kidney under stress conditions)

  • Peptide competition controls to confirm specificity

Following these best practices should yield specific, reproducible staining patterns for phosphorylated STK39 at S325 in tissue sections, enabling reliable analysis of its activation status in physiological and pathological contexts .

How can I troubleshoot weak or inconsistent signals when using Phospho-STK39 (S325) Antibody in Western blotting?

When encountering weak or inconsistent signals with Phospho-STK39 (S325) Antibody in Western blotting, implement this systematic troubleshooting approach:

• Sample preparation optimization:

  • Harvest cells/tissues rapidly and lyse immediately in cold buffer containing phosphatase inhibitors

  • Add phosphatase inhibitor cocktails (including sodium fluoride, sodium orthovanadate, and β-glycerophosphate)

  • Maintain samples at 4°C throughout processing to minimize phosphatase activity

  • Consider using specialized phosphoprotein extraction buffers for challenging samples

• Phosphorylation state enhancement:

  • Stimulate cells with conditions known to increase S325 phosphorylation before harvesting

  • For tissues, minimize time between collection and freezing/processing

  • Consider in vivo treatments that activate upstream pathways before tissue collection

• Technical adjustments to Western blot protocol:

  • Use PVDF membranes rather than nitrocellulose for better retention of phosphoproteins

  • Reduce washing stringency (lower concentrations of detergents in wash buffers)

  • Extend primary antibody incubation (overnight at 4°C) with gentle agitation

  • Try different blocking agents (BSA often works better than milk for phospho-antibodies)

• Signal enhancement strategies:

  • Implement enhanced chemiluminescence (ECL) detection systems with higher sensitivity

  • Consider using signal enhancers specifically designed for phosphoprotein detection

  • Increase exposure time while monitoring background levels

• Antibody optimization:

  • Test a range of primary antibody concentrations beyond the recommended starting dilution

  • Evaluate different lots if available, as phospho-antibody performance can vary by lot

  • Consider alternative phospho-STK39 antibodies targeting the same site from different vendors

If signal remains inconsistent, enrichment of phosphoproteins before Western blotting using phosphoprotein enrichment kits or immunoprecipitation with total STK39 antibodies followed by phospho-detection may significantly improve results .

What considerations should be taken into account when designing mass spectrometry experiments to study STK39 phosphorylation and its interactome?

Designing effective mass spectrometry experiments for STK39 phosphorylation and interactome analysis requires careful planning:

• Sample preparation strategies:

  • For interactome studies, consider expressing Flag-tagged STK39 as described in the literature

  • Implement SILAC or TMT labeling for quantitative comparison between experimental conditions

  • For phosphosite analysis, enrich phosphopeptides using TiO₂, IMAC, or phospho-specific antibodies

  • Consider comparing wild-type STK39 with S325A mutants to identify phosphorylation-dependent interactions

• Immunoprecipitation approach:

  • Use gentle lysis conditions to preserve protein-protein interactions (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40, 10% glycerol with protease inhibitors)

  • For phosphorylation studies, add phosphatase inhibitors to all buffers

  • Implement crosslinking strategies for capturing transient interactions

  • Consider tandem affinity purification for higher purity samples

• MS analysis parameters:

  • Use high-resolution MS/MS for improved phosphosite localization confidence

  • Implement neutral loss scanning for phosphopeptide detection

  • Consider targeted methods (PRM/MRM) for monitoring specific phosphosites

  • Use complementary fragmentation techniques (HCD, ETD) for comprehensive phosphopeptide analysis

• Data analysis considerations:

  • Apply appropriate statistical methods for interactome significance (compared to IgG controls)

  • Implement phosphosite localization scores to distinguish between possible phosphorylation sites

  • Use motif analysis tools to identify consensus sequences around phosphosites

  • Integrate with protein-protein interaction databases for network analysis

• Validation experiments:

  • Confirm key interactions by reciprocal co-IP and Western blotting

  • Validate functional significance of interactions using mutational studies

  • Use Phospho-STK39 (S325) Antibody to correlate MS findings with antibody-based detection

This comprehensive approach has successfully identified STK39 interactions with proteins like PLK1, providing insights into its role in signaling networks and disease processes .

How can Phospho-STK39 (S325) Antibody be used to evaluate potential therapeutic targets in hypertension research?

Utilizing Phospho-STK39 (S325) Antibody in hypertension research can provide valuable insights into potential therapeutic interventions:

• Screening of STK39 inhibitors:

  • Monitor S325 phosphorylation status as a biomarker of STK39 activity

  • Establish dose-response relationships between inhibitor concentration and phosphorylation reduction

  • Compare novel compounds against established kinase inhibitors using quantitative ELISA or Western blot analysis

  • Combine with functional readouts like cotransporter activity to establish structure-activity relationships

• Animal model validation:

  • SPAK-knockout mice manifest Gitelman syndrome phenotypes and exhibit blunted responses to hydrochlorothiazide

  • Quantify tissue-specific changes in STK39 phosphorylation in hypertensive vs. normotensive models

  • Correlate phosphorylation levels with physiological parameters (blood pressure, electrolyte balance)

  • Assess target engagement of candidate therapeutics through measurement of S325 phosphorylation

• Translational biomarker development:

  • Evaluate S325 phosphorylation in patient-derived samples as potential predictors of antihypertensive drug response

  • Correlate phosphorylation levels with clinical variables and treatment outcomes

  • Develop standardized protocols for phosphorylation assessment in clinical samples

  • Design immunohistochemistry panels combining Phospho-STK39 (S325) with markers of renal sodium transporters

• Mechanistic insights for drug development:

  • Map signaling networks connecting STK39 phosphorylation to downstream effectors

  • Identify tissue-specific regulation of STK39 activation

  • Determine temporal dynamics of phosphorylation in response to physiological stimuli

  • Use phosphorylation data to refine pharmacological targeting strategies

These applications of Phospho-STK39 (S325) Antibody can significantly contribute to the development of novel antihypertensive therapies, as STK39 has been identified as a promising therapeutic target .

What experimental approaches can elucidate the role of STK39 phosphorylation in cancer progression and potential therapeutic interventions?

To investigate STK39 phosphorylation in cancer and develop therapeutic strategies, consider these methodological approaches:

• Expression and phosphorylation profiling:

  • Analyze STK39 phosphorylation status across cancer types using tissue microarrays

  • Compare phosphorylation levels between tumor and adjacent normal tissues

  • Correlate phosphorylation status with clinical parameters and patient outcomes

  • Develop multiplexed IHC protocols combining Phospho-STK39 (S325) with markers of ERK pathway activation

• Functional studies in cancer models:

  • Generate STK39-knockout cancer cell lines using CRISPR/Cas9 technology as described in the literature

  • Perform rescue experiments with wild-type vs. S325A/S325D mutants

  • Assess effects on proliferation, migration, invasion, and response to therapy

  • Conduct RNA-seq analysis to identify downstream effectors regulated by STK39 phosphorylation

• Signaling pathway integration:

  • Investigate the relationship between STK39 and the ERK signaling pathway in cancer contexts

  • Explore the functional significance of the STK39-PLK1 interaction identified by mass spectrometry

  • Map kinase cascades upstream and downstream of STK39 phosphorylation

  • Identify context-dependent regulation of STK39 in different cancer subtypes

• Therapeutic targeting strategies:

  • Screen for compounds that modulate STK39 phosphorylation at S325

  • Evaluate combination approaches targeting STK39 alongside established cancer therapeutics

  • Develop biomarker strategies using phospho-STK39 to predict treatment response

  • Design peptide inhibitors targeting specific protein-protein interactions dependent on S325 phosphorylation

• In vivo validation:

  • Develop xenograft models with phosphorylation-site mutants of STK39

  • Use patient-derived xenografts to validate findings in more clinically relevant models

  • Implement in vivo imaging of phosphorylation status using antibody-based approaches

  • Correlate treatment response with changes in STK39 phosphorylation

These approaches, centered around the use of Phospho-STK39 (S325) Antibody and complementary techniques, can provide critical insights into STK39's role in cancer and identify novel therapeutic vulnerabilities .

How can single-cell techniques be integrated with Phospho-STK39 (S325) Antibody to understand cellular heterogeneity in signaling responses?

Integration of single-cell technologies with Phospho-STK39 (S325) Antibody detection offers powerful approaches to characterize signaling heterogeneity:

• Single-cell phospho-flow cytometry:

  • Optimize fixation and permeabilization protocols for intracellular Phospho-STK39 (S325) detection

  • Develop multiplexed panels including other relevant phospho-proteins (p-ERK, p-p38)

  • Implement mass cytometry (CyTOF) for higher dimensionality analysis of signaling networks

  • Correlate STK39 phosphorylation with cell cycle status and lineage markers

• Spatial phosphoprotein analysis:

  • Apply multiplexed immunofluorescence with Phospho-STK39 (S325) Antibody in tissue sections

  • Implement cyclic immunofluorescence or imaging mass cytometry for expanded marker panels

  • Correlate spatial distribution of STK39 phosphorylation with tissue architecture

  • Integrate with spatial transcriptomics to link phosphorylation patterns with gene expression

• Single-cell phosphoproteomics integration:

  • Develop computational approaches to correlate single-cell RNA-seq data with bulk phosphoproteomics

  • Implement new techniques for single-cell resolution of protein phosphorylation

  • Create predictive models of STK39 activation based on transcriptional signatures

  • Validate predictions using Phospho-STK39 (S325) Antibody in selected cell populations

• Live-cell imaging approaches:

  • Design FRET-based biosensors for real-time monitoring of STK39 phosphorylation

  • Combine with optogenetic tools to precisely control STK39 activation

  • Implement microfluidic systems for controlled stimulation while monitoring phosphorylation

  • Correlate temporal dynamics of phosphorylation with cellular behaviors

These integrated approaches can reveal cell-to-cell variability in STK39 phosphorylation and activation, providing insights into how signaling heterogeneity contributes to tissue function in normal and disease states .

What are the current limitations of Phospho-STK39 (S325) Antibody technology and potential future improvements?

Current limitations and future directions for Phospho-STK39 (S325) Antibody technology include:

• Technical limitations:

  • Variability between antibody lots affecting reproducibility

  • Cross-reactivity with similar phosphorylation motifs in other proteins

  • Limited sensitivity for detecting low abundance phosphorylation

  • Challenges in multiplexing with other phospho-specific antibodies

• Methodological constraints:

  • Inability to capture dynamic phosphorylation changes in real-time

  • Loss of phosphorylation during sample processing

  • Challenges in quantifying absolute phosphorylation levels

  • Limited spatial resolution in tissue contexts

• Future technological improvements:

  • Development of recombinant antibody formats with improved consistency

  • Engineering higher affinity variants through directed evolution

  • Creation of proximity-based detection systems for improved specificity

  • Integration with emerging proteomics technologies for validation

• Emerging alternative approaches:

  • Phospho-specific nanobodies with superior tissue penetration

  • Mass spectrometry imaging for spatial phosphoproteomics

  • CRISPR-based endogenous tagging for live monitoring of phosphorylation

  • Aptamer-based detection systems with improved sensitivity

• Integration with computational approaches:

  • Machine learning algorithms to improve signal detection and quantification

  • Systems biology models incorporating phosphorylation dynamics

  • Network analysis tools to place STK39 phosphorylation in cellular context

  • Digital pathology platforms for automated phospho-protein quantification

Addressing these limitations through technological innovation will enhance the utility of Phospho-STK39 (S325) detection in research and potential clinical applications .

What are the most promising research directions involving Phospho-STK39 (S325) Antibody in the next five years?

Several high-potential research avenues involving Phospho-STK39 (S325) Antibody are emerging:

• Precision medicine applications:

  • Development of companion diagnostics for antihypertensive therapies

  • Stratification of cancer patients based on STK39 phosphorylation status

  • Integration into multi-biomarker panels for disease prognosis

  • Implementation in clinical trials for STK39-targeted therapeutics

• Systems biology integration:

  • Mapping comprehensive phosphorylation networks centered on STK39

  • Understanding tissue-specific regulation of STK39 phosphorylation

  • Elucidating cross-talk between STK39 and other stress-response pathways

  • Computational modeling of phosphorylation dynamics under various conditions

• Technological innovations:

  • Development of proximity ligation assays for detecting specific STK39 interactions

  • Implementation of advanced super-resolution microscopy for subcellular localization

  • Creation of STK39 activity biosensors for live-cell applications

  • Integration with organ-on-chip technologies for physiological modeling

• Therapeutic targeting:

  • Structure-based design of inhibitors targeting phosphorylation-dependent conformations

  • Development of proteolysis-targeting chimeras (PROTACs) for STK39 degradation

  • Exploration of context-specific vulnerabilities in cancer and other diseases

  • Design of peptide inhibitors disrupting key protein-protein interactions

These research directions leverage the specificity of Phospho-STK39 (S325) Antibody to advance our understanding of STK39 biology and develop novel therapeutic strategies for diseases involving its dysregulation .